$SNTI
Senti Biosciences, Inc.

2024 Q3 Form 10-Q Financial Statement

#000185427024000101 Filed on August 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.247M $4.205M
YoY Change -33.75% -56.29%
% of Gross Profit
Research & Development $8.655M $9.151M
YoY Change -4.81% -16.44%
% of Gross Profit
Depreciation & Amortization $946.0K $971.0K
YoY Change -29.93% 21.38%
% of Gross Profit
Operating Expenses $15.22M $13.36M
YoY Change -65.59% -35.08%
Operating Profit -$15.22M -$13.36M
YoY Change -65.32% -31.98%
Interest Expense $150.0K $236.0K
YoY Change -74.27% -70.28%
% of Operating Profit
Other Income/Expense, Net -$13.65M $2.153M
YoY Change -288.0% 129.53%
Pretax Income -$28.87M -$11.20M
YoY Change -21.17% -40.09%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$28.87M -$11.20M
YoY Change 93.43% -40.08%
Net Earnings / Revenue
Basic Earnings Per Share -$6.31 -$2.45
Diluted Earnings Per Share -$6.31 -$2.45
COMMON SHARES
Basic Shares Outstanding 4.579M shares 45.76M shares
Diluted Shares Outstanding 4.577M shares 4.572M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.48M $15.86M
YoY Change -73.4% -73.39%
Cash & Equivalents $10.50M $15.90M
Short-Term Investments
Other Short-Term Assets $8.000K $20.00K
YoY Change -98.36% -85.61%
Inventory
Prepaid Expenses $1.481M $2.046M
Receivables $74.00K $39.00K
Other Receivables $1.113M $18.62M
Total Short-Term Assets $17.38M $44.34M
YoY Change -78.0% -30.17%
LONG-TERM ASSETS
Property, Plant & Equipment $22.22M $23.25M
YoY Change -15.95% -60.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $88.00K $76.00K
YoY Change -50.28% -80.66%
Total Long-Term Assets $40.34M $42.57M
YoY Change -23.54% -46.87%
TOTAL ASSETS
Total Short-Term Assets $17.38M $44.34M
Total Long-Term Assets $40.34M $42.57M
Total Assets $57.72M $86.91M
YoY Change -56.19% -39.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $793.0K $1.181M
YoY Change -60.17% -54.31%
Accrued Expenses $7.464M $6.890M
YoY Change 13.09% -6.89%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $103.0K $101.0K
YoY Change 3.0% 1.0%
Total Short-Term Liabilities $9.064M $9.068M
YoY Change -10.38% -13.03%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.543M $33.70M
YoY Change -93.43% -5.61%
Total Long-Term Liabilities $2.543M $33.70M
YoY Change -93.43% -5.61%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.064M $9.068M
Total Long-Term Liabilities $2.543M $33.70M
Total Liabilities $41.73M $42.77M
YoY Change -14.55% -7.46%
SHAREHOLDERS EQUITY
Retained Earnings -$296.5M -$267.7M
YoY Change 31.43% 27.05%
Common Stock $1.000K $1.000K
YoY Change -75.0% -75.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.99M $44.15M
YoY Change
Total Liabilities & Shareholders Equity $57.72M $86.91M
YoY Change -56.19% -39.49%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$28.87M -$11.20M
YoY Change 93.43% -40.08%
Depreciation, Depletion And Amortization $946.0K $971.0K
YoY Change -29.93% 21.38%
Cash From Operating Activities -$7.866M -$8.345M
YoY Change -48.86% -39.0%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $60.00K $0.00
YoY Change -99.74% -100.0%
Cash From Investing Activities $60.00K $0.00
YoY Change -99.72% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.440M 0.000
YoY Change -8233.33% -100.0%
NET CHANGE
Cash From Operating Activities -7.866M -8.345M
Cash From Investing Activities 60.00K 0.000
Cash From Financing Activities 2.440M 0.000
Net Change In Cash -5.366M -8.345M
YoY Change -193.48% -268.93%
FREE CASH FLOW
Cash From Operating Activities -$7.866M -$8.345M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$7.866M -$8.345M
YoY Change -54.35% -51.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2046000 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2546000 usd
CY2024Q2 us-gaap Deposits Assets Current
DepositsAssetsCurrent
87000 usd
CY2023Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
42000 usd
CY2023Q4 snti Accrued Professional Fees Other Current
AccruedProfessionalFeesOtherCurrent
2363000 usd
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3271771 shares
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1447279 shares
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19406000 usd
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4572432 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4572432 shares
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-267658000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-244344000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
44148000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
66913000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
86913000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
119484000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
687000 usd
CY2022Q2 snti Reverse Recapitalization Contingent Consideration Equity Earnout Period Threshold Trading Days
ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays
P20D
CY2024Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
0 usd
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
20000 usd
CY2024Q2 snti Early Exercise Liability Noncurrent
EarlyExerciseLiabilityNoncurrent
0 usd
CY2023Q4 snti Early Exercise Liability Noncurrent
EarlyExerciseLiabilityNoncurrent
10000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
42765000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
52571000 usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
311805000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
311256000 usd
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
CY2024Q2 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
0 usd
CY2023Q2 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
250000 usd
CY2024Q2 us-gaap Revenues
Revenues
0 usd
CY2023Q2 us-gaap Revenues
Revenues
937000 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9151000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6876000 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4205000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9249000 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
13356000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
16125000 usd
us-gaap Operating Expenses
OperatingExpenses
29657000 usd
us-gaap Operating Expenses
OperatingExpenses
32376000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13356000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-15188000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-29657000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-30153000 usd
CY2024Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
236000 usd
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
794000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
568000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1855000 usd
CY2024Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 usd
CY2023Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-148000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-207000 usd
CY2024Q2 us-gaap Sublease Income
SubleaseIncome
1587000 usd
CY2023Q2 us-gaap Sublease Income
SubleaseIncome
0 usd
us-gaap Sublease Income
SubleaseIncome
3047000 usd
us-gaap Sublease Income
SubleaseIncome
0 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12000 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2153000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
938000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6343000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2050000 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-11203000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-14250000 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-23314000 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-28103000 usd
CY2024Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 usd
CY2023Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-4447000 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-9316000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-11203000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-18697000 usd
us-gaap Net Income Loss
NetIncomeLoss
-23314000 usd
us-gaap Net Income Loss
NetIncomeLoss
-37419000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-3000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1000 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11203000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18700000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23314000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37420000 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.45
CY2024Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.45
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-3.22
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-3.22
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-5.10
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-5.10
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-6.36
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-6.36
CY2024Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0
CY2024Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
CY2023Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-1.00
CY2023Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-1.00
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.45
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.45
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.22
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.10
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.10
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4572010 shares
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4572010 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4427726 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4427726 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4571377 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4571377 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4417411 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4417411 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
66913000 usd
CY2024Q1 snti Stock Issued During Period Value Vesting Of Early Exercise Of Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions
34000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1258000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-12111000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
56094000 usd
CY2024Q2 snti Stock Issued During Period Value Vesting Of Early Exercise Of Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions
33000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-776000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-11203000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
44148000 usd
CY2023Q1 snti Stock Issued During Period Value Vesting Of Early Exercise Of Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions
34000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3763000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
2000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-18722000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
112340000 usd
CY2023Q2 snti Stock Issued During Period Value Vesting Of Early Exercise Of Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions
34000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
308000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3434000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-3000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-18697000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
97416000 usd
us-gaap Net Income Loss
NetIncomeLoss
-23314000 usd
us-gaap Net Income Loss
NetIncomeLoss
-37419000 usd
us-gaap Depreciation
Depreciation
1955000 usd
us-gaap Depreciation
Depreciation
1221000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
973000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
919000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
952000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-207000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
482000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
7197000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-70000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
74000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-5000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-54000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
885000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3119000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2082000 usd
snti Increase Decrease In Deferred Sublease Income
IncreaseDecreaseInDeferredSubleaseIncome
-191000 usd
snti Increase Decrease In Deferred Sublease Income
IncreaseDecreaseInDeferredSubleaseIncome
0 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-635000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1929000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
1035000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20027000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29979000 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
17990000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
0 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
37000000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10176000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
8834000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
308000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
62000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
246000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20042000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20899000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39448000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60987000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19406000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40088000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15860000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36752000 usd
CY2024Q2 us-gaap Restricted Cash
RestrictedCash
3546000 usd
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
3336000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19406000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40088000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1796000 usd
snti Cash Acquired Through Reverse Recapitalization
CashAcquiredThroughReverseRecapitalization
300100000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-267700000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-244300000 usd
us-gaap Net Income Loss
NetIncomeLoss
-23300000 usd
us-gaap Net Income Loss
NetIncomeLoss
-37400000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15900000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35900000 usd
snti Number Of Business Activities
NumberOfBusinessActivities
1 businessactivitiy
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 reportablesegment
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the valuation of stock-based awards, the accrual for research and development expenses, the valuation of GeneFab Option, the valuation of GeneFab Economic Share, the valuation of the GeneFab Note Receivable, the discount rate used to discount future cash flows for the impairment of long-lived assets, and the determination of the incremental borrowing rate. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments that potentially subject the Company to a significant concentration of credit risk consist of cash and cash equivalents are maintained in checking and money market accounts at one financial institution, which at times, may exceed federally insured limits. As of June 30, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2023, the Company has not experienced any credit losses in such accounts or investments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of June 30, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">he Company has prepaid future manufacturing and research services of $7.7 million under the development and manufacturing services agreement entered into with GeneFab, a related party. The Company also has a receivable from GeneFab under the framework agreement with a fair value of $17.4 million, subject to satisfaction of certain conditions. The prepaid expense and receivable balances from GeneFab potentially subject the Company to a significant concentration of credit risk if the Company is unable to realize these balances. Refer to Note 3. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">GeneFab Transaction</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, for further details of the GeneFab transaction.</span></div>
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19406000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39448000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39448000 usd
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
20000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
195000 usd
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
31113000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
31520000 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7860000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6182000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23253000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25338000 usd
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1343000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3555000 usd
CY2024Q2 snti Accrued Professional Fees Other Current
AccruedProfessionalFeesOtherCurrent
1142000 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
76000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
9000 usd
CY2024Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
2561000 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
5927000 usd
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1315000 usd
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1320000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
2631000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
2629000 usd
CY2024Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
8000 usd
CY2023Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
25000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
17000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
56000 usd
CY2024Q2 us-gaap Variable Lease Cost
VariableLeaseCost
235000 usd
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
378000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
503000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
622000 usd
CY2024Q2 us-gaap Lease Cost
LeaseCost
1558000 usd
CY2023Q2 us-gaap Lease Cost
LeaseCost
1723000 usd
us-gaap Lease Cost
LeaseCost
3151000 usd
us-gaap Lease Cost
LeaseCost
3307000 usd
snti Operating Lease Proceeds Payments
OperatingLeaseProceedsPayments
-3583000 usd
snti Operating Lease Proceeds Payments
OperatingLeaseProceedsPayments
-675000 usd
snti Right Of Use Asset Obtained In Exchange For Operating Lease Liability Net Of Adjustments
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityNetOfAdjustments
0 usd
snti Right Of Use Asset Obtained In Exchange For Operating Lease Liability Net Of Adjustments
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityNetOfAdjustments
-30000 usd
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y1M6D
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y10M24D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.092
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.091
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
3668000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
7478000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
7712000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5769000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
4855000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
5000000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
14529000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
49011000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
13371000 usd
CY2024Q2 snti Tenant Improvement Allowance Remaining Amount
TenantImprovementAllowanceRemainingAmount
0 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
35640000 usd
CY2024Q2 us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
1240000 usd
CY2023Q2 us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
0 usd
us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
2443000 usd
us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
0 usd
CY2024Q2 us-gaap Operating Lease Variable Lease Income
OperatingLeaseVariableLeaseIncome
347000 usd
CY2023Q2 us-gaap Operating Lease Variable Lease Income
OperatingLeaseVariableLeaseIncome
0 usd
us-gaap Operating Lease Variable Lease Income
OperatingLeaseVariableLeaseIncome
604000 usd
us-gaap Operating Lease Variable Lease Income
OperatingLeaseVariableLeaseIncome
0 usd
CY2024Q2 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
1587000 usd
CY2023Q2 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
0 usd
us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
3047000 usd
us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
0 usd
CY2024Q2 us-gaap Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
2434000 usd
CY2024Q2 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
4919000 usd
CY2024Q2 us-gaap Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
5069000 usd
CY2024Q2 us-gaap Lessor Operating Lease Payments To Be Received Three Years
LessorOperatingLeasePaymentsToBeReceivedThreeYears
4903000 usd
CY2024Q2 us-gaap Lessor Operating Lease Payments To Be Received Four Years
LessorOperatingLeasePaymentsToBeReceivedFourYears
4891000 usd
CY2024Q2 us-gaap Lessor Operating Lease Payments To Be Received Five Years
LessorOperatingLeasePaymentsToBeReceivedFiveYears
5037000 usd
CY2024Q2 us-gaap Lessor Operating Lease Payments To Be Received Thereafter
LessorOperatingLeasePaymentsToBeReceivedThereafter
13258000 usd
CY2024Q2 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
40511000 usd
CY2024Q2 snti Number Of Votes Per Common Share
NumberOfVotesPerCommonShare
1 vote
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0 usd
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4655115 shares
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4483216 shares
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q2 snti Reverse Recapitalization Contingent Consideration Equity Shares
ReverseRecapitalizationContingentConsiderationEquityShares
200000 shares
CY2022Q2 snti Reverse Recapitalization Contingent Consideration Equity Number Of Tranches
ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches
2 tranche
CY2022Q2 snti Reverse Recapitalization Contingent Consideration Equity Shares Per Tranche
ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche
100000 shares
CY2022Q2 snti Reverse Recapitalization Contingent Consideration Equity Earnout Period Threshold Consecutive Trading Days
ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays
P30D
us-gaap Revenues
Revenues
0 usd
CY2024Q2 us-gaap Revenues
Revenues
0 usd
CY2024Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
0 usd
CY2023Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
200000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
0 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
600000 usd
CY2021Q4 us-gaap Government Assistance Award Amount
GovernmentAssistanceAwardAmount
2000000.0 usd
CY2021 us-gaap Government Assistance Transaction Duration
GovernmentAssistanceTransactionDuration
P2Y
us-gaap Revenues
Revenues
0 usd
CY2024Q2 us-gaap Revenues
Revenues
0 usd
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
-776000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3434000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
482000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7197000 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
0 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-11203000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-14250000 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-23314000 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-28103000 usd
CY2024Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 usd
CY2023Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-4447000 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-9316000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-11203000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-18697000 usd
us-gaap Net Income Loss
NetIncomeLoss
-23314000 usd
us-gaap Net Income Loss
NetIncomeLoss
-37419000 usd
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4572010 shares
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4572010 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4427726 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4427726 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4571377 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4571377 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4417411 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4417411 shares
CY2024Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.45
CY2024Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.45
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-3.22
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-3.22
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-5.10
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-5.10
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-6.36
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-6.36
CY2024Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0
CY2024Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
CY2023Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-1.00
CY2023Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-1.00
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-2.11
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-2.11
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.45
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.45
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.22
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.10
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.10
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.47
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.47
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3271771 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1447279 shares
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
46000000.0 usd
CY2021Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P11Y
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001854270-24-000101-index-headers.html Edgar Link pending
0001854270-24-000101-index.html Edgar Link pending
0001854270-24-000101.txt Edgar Link pending
0001854270-24-000101-xbrl.zip Edgar Link pending
a2024063010qex311.htm Edgar Link pending
a2024063010qex312.htm Edgar Link pending
a2024063010qex321.htm Edgar Link pending
a2024063010qex322.htm Edgar Link pending
a20240630ex101senti-genefa.htm Edgar Link pending
a20240630ex103consultingag.htm Edgar Link pending
a20240630ex104consultingag.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snti-20240630.htm Edgar Link pending
snti-20240630.xsd Edgar Link pending
snti-20240630_def.xml Edgar Link unprocessable
snti-20240630_lab.xml Edgar Link unprocessable
snti-20240630_htm.xml Edgar Link completed
snti-20240630_cal.xml Edgar Link unprocessable
snti-20240630_pre.xml Edgar Link unprocessable